• Citer

Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: Are different antiretroviral drugs associated with different lipid profiles?

par Fontas, Eric;Van Leth, F.;Sabin, Caroline;Friis-Møller, Nina;Rickenbach, Martin;d'Arminio Monforte, Antonella;Kirk, Ole;Dupon, Michel;Morfeldt, Linda;Mateu, Silvia;Petoumenos, Kathy;El-Sadr, Wafaa;De Wit, Stéphane ;Lundgren, Jens D;Pradier, Christian;Reiss, Peter
Référence The Journal of infectious diseases, 189, 6, page (1056-1074)
Publication Publié, 2004-03

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Résumé :

Levek of triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-c), and high-density lipoprotein cholesterol (HDL-c), as well as the TC:HDL-c ratio, were compared in patients receiving different antiretroviral therapy regimens. Patients receiving first-line regimens including protease inhibitors (PIs) had higher TC and TG levels and TC:HDL-c ratios than did antiretroviral-naive patients; patients receiving 2 PIs had higher levels of each lipid. Ritonavir-containing regimens were associated with higher TC and TG levels and TC:HDL-c ratios than were indinavir-containing regimens; however, receipt of nelfinavir was associated with reduced risk of lower HDL-c levels, and receipt of saquinavir was associated with lower TC: HDL-c ratios. Patients receiving non-nucleoside reverse-transcriptase inhibitors had higher levels of TC and LDL-c than did antiretroviral-naive patients, although the risk of having lower HDL-c levels was lower than that in patients receiving a single PI. Efavirenz was associated with higher levels of TC and TG than was nevirapine.